Mylan’s Lower-Cost EpiPen May Not Hurt Drugmaker’s Sales Much image

Bloomberg, August 29, 2016
Cynthia Koons and Zachary Tracer, quoting Rachel E. Sachs (Academic Fellow alumna)

Links

Read the Full Article

[...] Meanwhile, by introducing its generic, Mylan will set the market price for subsequent competitors.

“Now that there’s a product on the market for $300, any generic that enters knows that that’s the new benchmark,” said Rachel Sachs, an associate professor of law at Washington University in St. Louis. “You have to come in under $300.” [...]

Read more here!

health law policy pharmaceuticals rachel sachs